Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | PTGES2 | Q9H7Z7 | 6/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | CCR4 | P51679 | 3/20 | 0.46 |
| ▸ | SGK1 | O00141 | 1/20 | 0.44 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629338 | 0.90 | SLC22A12 (0.53) | ALDH1A1PGRLMNAMEN1KMT2A | |
| SCHEMBL13852948 | 0.88 | ALDH1A1 (0.61) | ALDH1A1PTGES2PGRLMNAMEN1 | |
| SCHEMBL13629401 | 0.86 | ALDH1A1 (0.65) | ALDH1A1PTGES2PGRLMNAMEN1 | |
| SCHEMBL13629427 | 0.85 | ALDH1A1 (0.54) | ALDH1A1LMNAMEN1THRBKMT2A | |
| SCHEMBL16325865 | 0.84 | ALDH1A1 (0.63) | ALDH1A1PTGES2PGRLMNAMEN1 | |
| SCHEMBL13615274 | 0.82 | PTGES2 (0.52) | ALDH1A1PTGES2PGRLMNAMEN1 | |
| SCHEMBL13629411 | 0.81 | PPARG (0.55) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL13629296 | 0.81 | ALDH1A1 (0.57) | ALDH1A1LMNAMEN1HPGDKMT2A | |
| SCHEMBL13629290 | 0.81 | BRD4 (0.52) | ALDH1A1THRBHPGDSGK1 | |
| SCHEMBL13629279 | 0.80 | PGR (0.60) | ALDH1A1PTGES2PGRLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | ALDH1A1 2057/4885PTGES2 547/4885PGR 1506/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | ALDH1A1 2121/4885PTGES2 841/4885PGR 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.